Released August 08, 2019 | SUGAR LAND
en
Contract development and manufacturing organization (CDMO) Cambrex is being purchased by private-equity firm Permira Funds. The $2.4 billion transaction, expected to close during fourth-quarter 2019, is just another deal in the Pharma-Bio Industry's ongoing merger & acquisition spree.
Cambrex is in the midst of a $15 million upgrade in High Point, North Carolina, including its current 35,000-square-foot facility (4180 Mendenhall Oaks Parkway) and another 40,000-square-foot building (4170 Mendenhall Oaks Parkway), which is currently occupied by vTv Therapeutics, to increase contract production capacity of small molecule Active Pharmaceutical Ingredients (APIs) and intermediates.
Cambrex is in the midst of a $15 million upgrade in High Point, North Carolina, including its current 35,000-square-foot facility (4180 Mendenhall Oaks Parkway) and another 40,000-square-foot building (4170 Mendenhall Oaks Parkway), which is currently occupied by vTv Therapeutics, to increase contract production capacity of small molecule Active Pharmaceutical Ingredients (APIs) and intermediates.
